Citation: | GUO Huimei, PAN Ling, HE Jianhui, HUA Luoming, CAO Zhixin, XUE Lei. Related Factors of Thrombosis in Patients with Myeloproliferative Neoplasms[J]. Cancer Research on Prevention and Treatment, 2013, 40(10): 958-960. DOI: 10.3971/j.issn.1000-8578.2013.10.010 |
[1] |
Baxter EJ,Scott LM,Campbell PJ,et al.Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative diseases[J]. Lancet, 2005, 365 (9464):1054-61.
|
[2] |
Antonioli E,Guglielmelli P,Poli G,et al.Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia[J].Haematologica,2008,93(1): 41-8.
|
[3] |
Reikvam H, Tiu RV. Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera[J]. Leukemia,2 012,26(4):563-71.
|
[4] |
Campbell PJ, Scott LM, Buck G, et al. Defi nition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study[J]. Lancet,2005,366(9501):1945-53.
|
[5] |
De Stefano V,Rossi E, Za T,et al.JAK2 V617F mutational frequency in essential thrombocythemia associated with splanchnic or cerebral vein thrombosis[J]. Am J Hematol,2011,86 (6):526-8.
|
[6] |
Landolfi R, Di Gennaro L, Barbui T, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera[J]. Blood,2007,109(6):2446-52.
|
[7] |
Landolfi R,Di Gennaro L,Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation[J].Leukemia,2008,22(11):2020-8.
|
[8] |
Carobbio A,Finazzi G,Guerini V,et al.Leukocytosia is a risk factor for thrombosis in essential thrombocythemia:interaction with treatment,standard risk factors,and JAK2 mutation status[J].Blood,2007,109(6):2310-3.
|